S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
BLGO · BioLargo, Inc.
OTC MARKETS - Real Time Price • USD
$0.07
-0.00
(-4.41%)
● Overnight
DAY'S RANGE
$0.07
$0.07
$0.07
52-WEEK RANGE
$0.07
$0.07
$0.20
What's happening
- BLGO is down 4.41% today, trading at $0.07. — Live quote
- It's trading within 3% of its 52-week low ($0.07). (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.01 actual vs. $-0.01 estimated (+2.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 4
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BLGO
-62.40%
vs S&P 500
-75.18%
1-YEAR RETURN
BLGO
-63.06%
vs S&P 500
-77.62%
6-MONTH RETURN
BLGO
-52.53%
3-MONTH RETURN
BLGO
-39.90%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.01
Est. $-0.01
BEAT +2.0%
2026-04-26 (Q1 2026)
$-0.01
Est. $-0.01
BEAT +2.0%
2026-01-26 (Q4 2025)
$-0.01
Est. $-0.01
MISS -17.6%
2025-10-26 (Q3 2025)
$-0.01
Est. $-0.01
BEAT +2.0%
Valuation Measures & Ratios
Enterprise Value4$26.0M
Forward P/E5—
PEG Ratio6-0.01
Price / Sales (TTM1)5.58
Price / Book729.00
EV4 / Revenue6.37
EV4 / EBITDA—
Profit Margin-354.76%
Operating Margin-443.86%
Return on Equity (ROE8)-244.01%
Return on Assets (ROA9)-177.32%
Avg Volume (3M)382,990
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short20
Change from Prior Settlement-98.04%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -55.1% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -354.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -63.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BLGO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | $675.0K | $458.0K | $372.0K | $1.4M | $1.5M | $1.7M | $2.1M | $2.2M |
| Operating income | -$3.7M | -$3.2M | -$7.2M | -$1.8M | -$1.9M | -$1.1M | -$890.0K | -$763.0K |
| Net income | — | — | — | — | — | — | — | — |
| EPS (basic) | $-0.01 | $-0.01 | $-0.02 | $-0.00 | $0.00 | $-0.00 | $-0.00 | $-0.00 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Jan '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $6.7M | $8.6M | $8.3M | $9.1M | $12.5M | $10.5M | — | $10.5M |
| Total liabilities | $9.4M | $8.8M | $6.8M | $5.9M | $6.4M | $5.4M | — | $4.5M |
| Stockholders' equity | -$1.9M | $1.8M | $4.0M | $6.6M | $8.8M | $7.6M | — | $8.9M |
| Total current assets | $3.5M | $5.4M | $5.1M | $5.8M | $9.2M | $7.2M | — | $7.1M |
| Total current liabilities | $4.8M | $4.9M | $5.1M | $3.5M | $4.1M | $3.4M | — | $2.6M |
| Cash & equivalents | $2.2M | $4.1M | $3.9M | $4.5M | $3.5M | $2.6M | — | $3.5M |
| Accounts receivable | $724.0K | $730.0K | $615.0K | $761.0K | $1.7M | $4.2M | — | $3.2M |
| Inventory | $303.0K | $292.0K | $310.0K | $409.0K | $444.0K | $369.0K | $310.0K | $330.0K |
| Property, plant & equipment | $1.8M | $1.6M | $1.6M | $1.7M | $1.7M | $1.7M | — | $1.7M |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $111.0K | $108.0K | $106.0K | $116.0K | $102.0K | $95.0K | — | $95.0K |
| Accounts payable | $874.0K | $838.0K | $1.0M | $789.0K | $1.2M | $1.2M | — | $826.0K |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | $46.0K | $319.0K | $280.0K | — | — | — | — | $0 |
| Short-term debt | — | — | — | $83.0K | $83.0K | — | — | $66.0K |
| Long-term debt | — | — | $2.1M | — | — | — | — | $1.1M |
| Common stock & paid-in capital | $217.0K | $214.0K | $213.0K | $208.0K | $205.0K | $202.0K | — | $202.0K |
| Retained earnings | -$166.3M | -$163.6M | -$161.3M | -$158.3M | -$151.8M | -$150.7M | — | -$149.5M |
| Accumulated other comprehensive income (loss) | -$206.0K | -$209.0K | -$207.0K | -$195.0K | -$203.0K | -$203.0K | — | -$183.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.1M | -$2.9M | -$1.6M | -$2.8M | -$2.1M | -$1.8M | -$1.9M | -$1.6M |
| Investing cash flow | -$160.0K | -$32.0K | -$13.0K | $256.0K | $192.0K | $0 | -$57.0K | -$39.0K |
| Financing cash flow | $1.3M | $3.2M | $952.0K | $3.6M | $2.8M | $866.0K | $1.6M | $764.0K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $722.0K | $699.0K | $1.0M | $844.0K | $492.0K | $615.0K | $799.0K | $237.0K |
| Change in accounts receivable | $7.0K | $115.0K | -$144.0K | -$410.0K | $1.3M | $1.1M | -$41.0K | $1.1M |
| Change in inventory | $11.0K | -$18.0K | -$99.0K | -$35.0K | $75.0K | $39.0K | $92.0K | $62.0K |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | $12.2M | — | — |
| Gross profit | $3.4M | $7.9M | $6.2M | $2.9M | $1.1M |
| Operating income | -$14.9M | -$4.3M | -$4.6M | -$5.4M | -$6.8M |
| Net income | — | — | — | — | — |
| EPS (basic) | $-0.04 | $-0.01 | $-0.01 | $-0.02 | $-0.03 |
| Operating margin | — | — | -$37 | — | — |
Balance sheet
| Line item | Dec '25 | Jan '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|---|
| Total assets | $8.3M | — | $10.5M | $8.2M | $4.9M |
| Total liabilities | $6.8M | — | $4.5M | $4.0M | $2.8M |
| Stockholders' equity | $4.0M | — | $8.9M | $6.8M | $4.9M |
| Total current assets | $5.1M | — | $7.1M | $6.4M | $3.2M |
| Total current liabilities | $5.1M | — | $2.6M | $2.7M | $1.6M |
| Cash & equivalents | $3.9M | — | $3.5M | $3.5M | $1.9M |
| Accounts receivable | $615.0K | — | $3.2M | $2.6M | $1.1M |
| Inventory | $310.0K | $310.0K | $330.0K | $153.0K | $120.0K |
| Property, plant & equipment | $1.6M | — | $1.7M | $662.0K | $287.0K |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | $106.0K | — | $95.0K | $70.0K | $124.0K |
| Accounts payable | $1.0M | — | $826.0K | $1.2M | $717.0K |
| Accrued liabilities | — | — | — | — | — |
| Deferred revenue (current) | $280.0K | — | $0 | $303.0K | $17.0K |
| Short-term debt | — | — | $552.0K | — | $100.0K |
| Long-term debt | $2.1M | — | $1.1M | — | — |
| Common stock & paid-in capital | $213.0K | — | $202.0K | $196.0K | $186.0K |
| Retained earnings | -$161.3M | — | -$149.5M | -$147.1M | -$143.6M |
| Accumulated other comprehensive income (loss) | -$207.0K | — | -$183.0K | -$277.0K | -$149.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$8.3M | -$3.2M | -$2.4M | -$2.8M | -$3.9M |
| Investing cash flow | $435.0K | -$1.3M | -$478.0K | -$271.0K | -$34.0K |
| Financing cash flow | $8.2M | $4.4M | $4.7M | $4.0M | $4.2M |
| Capital expenditures | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $3.0M | $2.1M | $2.1M | $2.1M | $1.9M |
| Change in accounts receivable | $1.8M | $569.0K | $1.6M | $551.0K | $29.0K |
| Change in inventory | -$20.0K | $177.0K | $89.0K | $35.0K | -$36.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BLGO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-31 to 2026-09-30
Recent transactions
- Most recent: CODE KENNETH REAY (Chief Science Officer) — Grant / award of 566,261 shares on 2026-09-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| CODE KENNETH REAY | Chief Science Officer | Grant / award | 2026-09-30 | 566,261 |
| CALVERT DENNIS P | President | Grant / award | 2026-09-30 | 931,886 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | CODE KENNETH REAY | Chief Science Officer | Grant / award | 566,261 | $0.08 |
| 2026-09-30 | CODE KENNETH REAY | Chief Science Officer | Gift | 2,000,000 | $0.00 |
| 2026-09-30 | CALVERT DENNIS P | President | Grant / award | 931,886 | $0.08 |
| 2026-09-30 | CALVERT DENNIS P | President | Gift | 2,000,000 | $0.00 |
| 2026-07-07 | CODE KENNETH REAY | Chief Science Officer | Grant / award | 532,567 | $0.11 |
| 2026-07-01 | CALVERT DENNIS P | President | Grant / award | 219,914 | $0.11 |
| 2026-06-30 | CALVERT DENNIS P | President | Grant / award | 699,569 | $0.11 |
| 2026-03-31 | CODE KENNETH REAY | Chief Science Officer | Grant / award | 69,444 | $0.16 |
| 2025-12-31 | CODE KENNETH REAY | Chief Science Officer | Grant / award | 54,803 | $0.18 |
| 2025-12-31 | CALVERT DENNIS P | President | Grant / award | 130,222 | $0.18 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:34 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-11 | 8-K | 2026-09-10 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about BLGO (BioLargo, Inc.). Links open the publisher — we don’t host full articles.
-
Form DEF 14A BIOLARGO For: 19 October By Investing.com
Investing.com UK · 2026-10-19 -
BioLargo Subsidiary Clyra Medical to Exhibit at SAWC Fall 2026 in Las Vegas
Yahoo · 2026-10-13 -
/C O R R E C T I O N from Tũ Nipi Water Solutions Ltd./
Yahoo Finance · 2026-09-15 -
BioLargo Inc (BLGO) (Q2 2026) Earnings Call Highlights: Navigating Setbacks and Building a ...
Yahoo Finance · 2026-09-11 -
BioLargo, Inc. (BLGO) Q2 2026 Earnings Call Transcript
Seeking Alpha · 2026-09-11 -
BioLargo Canada and Tu Nipi Form Indigenous-Led Partnership to Treat Oil Sands Process Water and More
Yahoo Finance · 2026-09-10 -
BioLargo, Inc. to Present at the Inaugural Nasdaq / LD Micro Summit on September 9, 2026
Yahoo Finance · 2026-09-01 -
BioLargo reports Q2 results
Seeking Alpha · 2026-08-17
No headlines in this category right now — try “All”.